Skip to main content

JPML Agrees To Centralize Elmiron Cases Over Vision Problems

JPML Agrees To Centralize Elmiron Cases Over Vision Problems

JPML Agrees To Centralize Elmiron Cases Over Vision Problems

Introduction

On Tuesday, the United States Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order, stating that the panel finds the centralization of Elmiron lawsuits in the District of New Jersey will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation.

Elmiron, also known by its generic name pentosan polysulfate sodium, or PPS, is an oral prescription drug used to treat pain/discomfort caused by bladder disorder interstitial cystitis, or IC. Recently, it has been discovered that the drug might lead to severe retinal injuries and permanent vision problems, following which many users have filed lawsuits.

In September, a consolidation request was filed by the plaintiffs who allege Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals for failing to warn about the side effects associated with the IC drug. The request included 63 actions pending in eleven districts, as listed on Schedule A of the attached transfer order, as well as 65 potentially-related actions. The plaintiffs asked the JPML to centralize the cases before Honorable Brian R. Martinotti in New Jersey.

The recent order notes that no responding party opposes the centralization, which will eliminate duplicative discovery, avoid inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary.

The centralization in the District of New Jersey is supported by plaintiffs in 42 actions, whereas some plaintiffs proposed alternative transferee districts of the Eastern District of Pennsylvania or the Southern District of Florida. Responding plaintiffs in 33 cases support centralization in the Eastern District of Pennsylvania, and plaintiffs in the Southern District of Ohio Gruppo action support centralization in the Southern District of Ohio.

The order concludes that the lawsuits listed on Schedule A and pending outside the District of New Jersey are transferred to the District of New Jersey and will be presided by Judge Martinotti for coordinated pretrial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Walgreens Settles Federal Opioid Case for $300 Million

Categories: Opioids

Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.

The U.S. Department of Justice announced on Monday…

Study: Opioid Use in Pregnancy May Shrink Newborn Brains

Categories: Opioids

New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…

Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting

Categories: Opioids

The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…

🛠️ You Have Unfinished Work. We’ll Finish It — Free Trial.            
Free Trial + 25% Off All DLs & Med Review Case Backlog!

Only 12 Firms Can Join – First Come, First Served